ppar agonist 1

PPAR agonist 1 is a dual PPAR α/γ agonist used for lowering blood glucose, lipid levels, cholesterol, and body weight.

Pparδ agonist 1 is an agonist of PPAR-δ(EC50 of 5.06 nM).

PPARα/γ agonist 1 is a potent dual PPARα/γ partial agonist with EC50 values of 28 nM for PPARα and 69 nM for PPARγ, making it a promising prototype for dyslipidemia and diabetes research [1].

PPARα agonist 1 is a complete and potent PPARα agonist.

PPARα/δ agonist 1 is a potent dual agonist with EC50 values of 7.0 nM for PPARα and 8.4 nM for PPARδ, exhibiting high selectivity for PPARγ (EC50: 1316.1 nM). Agonist 1 has potential for non-alcoholic steatohepatitis studies.

PPARγ agonist 1 is a potent agonist of PPARγ that efficiently activates hPPARγ without causing full agonism, thereby avoiding adverse effects. pparγ agonist 1 has shown research potential in cardiovascular diseases associated with metabolic disorders.

PPARγ agonist 10 (compound 33g) serves as a PPARγ agonist, enhancing insulin secretion, glucose uptake, and insulin sensitivity in βTC6 cells [1].

PPAR agonist6 (compound 5a) acts as an agonist for PPAR, exhibiting EC50 values of 3.6 μM and 2.6 μM for PPARα and PPARβ/δ respectively. Additionally, PPAR agonist6 inhibits the transactivation of a TNFα-dependent NF-κB-driven reporter gene in L929 cells [1].

SR-1903 is a modulator of retinoic acid receptor-related orphan receptor γ (RORγ) and liver X receptor (LXR). It is an inverse agonist of RORγ and an agonist of LXR. It also binds to peroxisome proliferator-activated receptor γ (PPAR) but does not activate it. SR-1903 inhibits LPS-induced expression of triggering receptor expressed on myeloid cells 1 (TREM-1). It also inhibits LPS-induced expression of the LXR target genes IL-6 and IL-33 and increases expression of ABCG1, FASN, and SCD-1. SR-1903 reduces the severity of collagen-induced arthritis. It reduces blood glucose levels in a glucose tolerance test, serum levels of total cholesterol and LDL, body weight, and fat mass in a mouse model of high-fat diet-induced obesity.

SNU-BP is an agonist of PPAR-gamma, inhibiting lipopolysaccharide (LPS)-induced NO production and pro-inflammatory cytokines. SNU-BP potentiates interleukin-4-induced arginase-1 expression, and promotes microglial polarization toward an M2 anti-inflammatory phenotype.

DSO-5a, a potent and selective orally active BB3 agonist, is a DMAKO-00 derivative that enhances ppar-γ activity via BB3 and stimulates ERK1/2 phosphorylation. It is utilized in diabetes-related research [1].

BAY-5094, a PPAR gamma (PPARG) inverse agonist, exhibits oral activity and is applicable in luminal bladder cancer research [1].

Sitofibrate, a clofibrate derivative, acts as a peroxisome proliferator-activated receptor-α (PPAR-α) agonist and serves as an antihyperlipidemic agent [1].